ELELYSO (Pfizer Laboratories Div Pfizer Inc)
Welcome to the PulseAid listing for the ELELYSO drug offered from Pfizer Laboratories Div Pfizer Inc. This Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC],Glucosylceramidase [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Pfizer Laboratories Div Pfizer Inc |
NON-PROPRIETARY NAME: | Taliglucerase alfa |
SUBSTANCE NAME: | TALIGLUCERASE ALFA |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC],Glucosylceramidase [Chemical/Ingredient] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2012-05-01 |
END MARKETING DATE: | 0000-00-00 |
ELELYSO HUMAN PRESCRIPTION DRUG Details:
Item Description | ELELYSO from Pfizer Laboratories Div Pfizer Inc |
LABELER NAME: | Pfizer Laboratories Div Pfizer Inc |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 200(U/5mL) |
START MARKETING DATE: | 2012-05-01 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0069-0106_aa3f45ad-4372-423f-9493-7060254d47cc |
PRODUCT NDC: | 0069-0106 |
APPLICATION NUMBER: | NDA022458 |
Other TALIGLUCERASE ALFA Pharmaceutical Manufacturers / Labelers: